August 25, 2016 | by Manisha Samy, ARK Analyst | Health
Prime Time for Companion Diagnostics We think the drug approval process remains convoluted, costly, and time-consuming, but it is about to change. The increased adoption of Companion Diagnostics (CDx)—tests that identify the most suitable patients for a particular treatment—holds much promise. ARK expects that CDx will improve patient outcomes demonstrably, reduce research and development spending […]April 21, 2016 | by Catherine Wood, ARK Invest CEO | HealthMentioned Companies: ILMN
Illumina is the cornerstone of our Genomic Revolution theme, and one of our highest conviction stocks. In response to an earnings preannouncement this week, it dropped as much as 25% in one day. While investors fear that it has passed its fastest growth rate, in our view Illumina is leading a genomic revolution that has […]October 30, 2014 | by James Bannon, ARK Analyst | Health
If World Health Organization (WHO) estimates are correct, the current Ebola outbreak could be out of control: as of mid-October, it has killed over 4,000 people and could cost the three most impacted countries Guinea, Liberia, and Sierra Leone $815 million dollars, or 6% of GDP. In the worst-case scenario, Liberia could lose over $230 […]May 27, 2014 | by James Bannon, ARK Analyst | Health
The declining cost of sequencing a human genome (in some instances, for as little as $1,000 per sequence) is creating a growing demand for tools that can sort, organize, analyze, and store the ever-increasing amount of biological data. If properly harnessed, data can be used for academic research and by pharmaceutical and diagnostic industries.